For autosomal recessive disorders, dogs with two copies of the variant are at risk of developing the condition. Dogs with one copy of the variant are considered carriers and are usually not at risk of developing the disorder. However, carriers of some complex variants grouped in this category may be associated with a low risk of developing the disorder. Individuals with one or two copies may pass the disorder-associated variant to their puppies if bred.
At risk dogs are highly likely to show signs of this disease in their lifetime.
Partner with your veterinarian to make a plan regarding your dog’s well-being, including any insights provided through genetic testing. If your pet is at risk or is showing signs of this disorder, then the first step is to speak with your veterinarian.
In Great Danes, typical clinical signs of CNM are general atrophy of the muscles, exercise intolerance, and exercise-related tremors of the muscles. Typically clinical signs appear at 6 to 8 months of age and progress with age. Most affected dogs will need to be euthanized before the age of 18 months due to severe weakness of the muscles.
Treatment is supportive care. Humane euthanasia for affected dogs is often elected.
There are many responsibilities to consider when breeding dogs. Regardless of test results it is important that your dog is in good general health and that you are in a position to care for the puppies if new responsible owners are not found. For first time or novice breeders, advice can be found at most kennel club websites.
This disease is autosomal recessive meaning that two copies of the mutation are needed for disease signs to develop. A carrier dog with one copy of the CNM mutation can be safely bred with a clear dog with no copies of the CNM mutation. About half of the puppies will have one copy (carriers) and half will have no copies of the CNM mutation. Puppies in a litter which is expected to contain carriers should be tested prior to breeding. Please note: It is possible that disease signs similar to the ones caused by the CNM mutation could develop due to a different genetic or clinical cause.
All coordinates reference CanFam3.1
Böhm, J., Vasli, N., Maurer, M., Cowling, B., Shelton, G. D., Kress, W., … Laporte, J. (2013). Altered Splicing of the BIN1 Muscle-Specific Exon in Humans and Dogs with Highly Progressive Centronuclear Myopathy. PLoS Genetics, 9(6). View the article
Gentilini, F., Zambon, E., Gandini, G., Rosati, M., Spadari, A., Romagnoli, N., … Gernone, F. (2011). Frequency of the allelic variant of the ptpla gene responsible for centronuclear myopathy in Labrador retriever dogs as assessed in Italy. Journal of Veterinary Diagnostic Investigation, 23(1), 124–126. View the article
Pelé, M., Tiret, L., Kessler, J. L., Blot, S., & Panthier, J. J. (2005). SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs. Human Molecular Genetics, 14(11), 1417–1427. View the article